{"id":305447,"date":"2026-10-13T14:08:04","date_gmt":"2026-10-13T08:38:04","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=305447"},"modified":"2026-10-13T14:08:04","modified_gmt":"2026-10-13T08:38:04","slug":"lalpathlab-best-stock-in-its-sector","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/lalpathlab-best-stock-in-its-sector\/","title":{"rendered":"Is Dr. Lal PathLabs the Best Stock in Its Sector? A Look at the Numbers"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Dr. Lal PathLabs CMP Rs 1,950 (13 Oct 2026). Market cap Rs 33,058 Cr. ROE 20.13%. P\/E 60.51x versus Industry P\/E 62.56x.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">Dr. Lal PathLabs is one of the names investors compare when screening the Healthcare sector, built on a 20.13% return on equity and a P\/E of 60.51x against an Industry P\/E of 62.56x. Whether Dr. Lal PathLabs is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Healthcare sector peers, so you can judge that for yourself.<\/p>\n<\/p><\/div>\n<p>Is <a href=\"https:\/\/univest.in\/stocks\/lalpathlab\/dr-lal-pathlabs-ltd-share-price-today\">Dr. Lal PathLabs<\/a> the best stock in its sector? The stock trades on the NSE at Rs 1,950 as of 13 October 2026, within its 52-week range of Rs 1,272.60 to Rs 2,038.60. Dr. Lal PathLabs Ltd, headquartered in New Delhi, is one of India&#8217;s largest diagnostic chains, running laboratories, collection centres and a home sample collection network.<\/p>\n<p>Dr. Lal PathLabs sits in the Healthcare sector, and its 20.13% ROE and 60.51x P\/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector&#8217;s Industry P\/E benchmark.<\/p>\n<p style=\"font-style:italic;color:#000000;margin:14px 0;\">Also read &#8211; <a href=\"https:\/\/univest.in\/blogs\/abbott-india-best-stock-in-its-sector\">Is Abbott India the Best Stock in Its Sector? A Look at the Numbers<\/a><\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=lalpathlab-best-stock-in-its-sector\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/lalpathlab-best-stock-in-its-sector\/#About_Dr_Lal_PathLabs\" title=\"About Dr. Lal PathLabs\">About Dr. Lal PathLabs<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/lalpathlab-best-stock-in-its-sector\/#Is_Dr_Lal_PathLabs_the_Best_Stock_in_Its_Sector\" title=\"Is Dr. Lal PathLabs the Best Stock in Its Sector?\">Is Dr. Lal PathLabs the Best Stock in Its Sector?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/lalpathlab-best-stock-in-its-sector\/#How_Dr_Lal_PathLabs_Compares_Against_Its_Healthcare_Sector_Peers\" title=\"How Dr. Lal PathLabs Compares Against Its Healthcare Sector Peers\">How Dr. Lal PathLabs Compares Against Its Healthcare Sector Peers<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/lalpathlab-best-stock-in-its-sector\/#What_Makes_Dr_Lal_PathLabs_Worth_Watching_in_Healthcare\" title=\"What Makes Dr. Lal PathLabs Worth Watching in Healthcare\">What Makes Dr. Lal PathLabs Worth Watching in Healthcare<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/lalpathlab-best-stock-in-its-sector\/#Dr_Lal_PathLabs_Valuation_Is_It_Justified\" title=\"Dr. Lal PathLabs Valuation: Is It Justified?\">Dr. Lal PathLabs Valuation: Is It Justified?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/lalpathlab-best-stock-in-its-sector\/#How_to_Track_Dr_Lal_PathLabs_Before_You_Invest\" title=\"How to Track Dr. Lal PathLabs Before You Invest\">How to Track Dr. Lal PathLabs Before You Invest<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/lalpathlab-best-stock-in-its-sector\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/lalpathlab-best-stock-in-its-sector\/#Is_Dr_Lal_PathLabs_the_best_stock_in_its_sector\" title=\"Is Dr. Lal PathLabs the best stock in its sector?\">Is Dr. Lal PathLabs the best stock in its sector?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/lalpathlab-best-stock-in-its-sector\/#What_is_the_current_share_price_of_Dr_Lal_PathLabs\" title=\"What is the current share price of Dr. Lal PathLabs?\">What is the current share price of Dr. Lal PathLabs?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/lalpathlab-best-stock-in-its-sector\/#What_sector_does_Dr_Lal_PathLabs_belong_to\" title=\"What sector does Dr. Lal PathLabs belong to?\">What sector does Dr. Lal PathLabs belong to?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/lalpathlab-best-stock-in-its-sector\/#How_does_Dr_Lal_PathLabs_compare_to_its_sector_peers_on_PE\" title=\"How does Dr. Lal PathLabs compare to its sector peers on P\/E?\">How does Dr. Lal PathLabs compare to its sector peers on P\/E?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/lalpathlab-best-stock-in-its-sector\/#What_is_Dr_Lal_PathLabss_return_on_equity\" title=\"What is Dr. Lal PathLabs&#8217;s return on equity?\">What is Dr. Lal PathLabs&#8217;s return on equity?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/lalpathlab-best-stock-in-its-sector\/#Should_I_invest_in_Dr_Lal_PathLabs_based_on_its_sector_position\" title=\"Should I invest in Dr. Lal PathLabs based on its sector position?\">Should I invest in Dr. Lal PathLabs based on its sector position?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"About_Dr_Lal_PathLabs\"><\/span><strong>About Dr. Lal PathLabs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Dr. Lal PathLabs Ltd, headquartered in New Delhi, is one of India&#8217;s largest diagnostic chains, running laboratories, collection centres and a home sample collection network. Pathology and diagnostic tests for patients, doctors and hospitals are its revenue source. The stock trades about 4 percent below its 52-week high and about 53 percent above its 52-week low. At a market capitalisation of Rs 33,058 Cr, it is tracked as part of the Healthcare sector on Univest.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Is_Dr_Lal_PathLabs_the_Best_Stock_in_Its_Sector\"><\/span><strong>Is Dr. Lal PathLabs the Best Stock in Its Sector?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Dr. Lal PathLabs makes its case as the best stock in its sector primarily on return on equity and balance sheet strength, combining a 20.13% ROE with a 60.51x P\/E against the sector&#8217;s 62.56x Industry P\/E. Dr. Lal PathLabs&#8217; 60.51x P\/E is slightly below the 62.56x Industry P\/E and below the 67.40x peer average, backed by a 20.13% ROE that is higher than both Metropolis Healthcare and Vijaya Diagnostic Centre and a debt to equity ratio of 0.08, the lowest in the peer table.<\/p>\n<table style=\"width:100%;border-collapse:collapse;\">\n<tr>\n<th style=\"border:1px solid #ddd;padding:8px;text-align:left;\">Metric<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;text-align:left;\">Dr. Lal PathLabs<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">CMP (NSE)<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Rs 1,949.50<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">52-Week High \/ Low<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Rs 2,038.60 \/ Rs 1,272.60<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Market Cap<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Rs 33,058 Cr<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">P\/E (TTM) vs Industry P\/E<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">60.51x vs 62.56x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">P\/B<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">13.18<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">ROE<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">20.13%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">EPS (TTM)<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Rs 32.55<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Dividend Yield<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">1.04%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Debt to Equity<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">0.08<\/td>\n<\/tr>\n<\/table>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Compare Dr. Lal PathLabs Against Other Healthcare Sector Stocks<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_Dr_Lal_PathLabs_Compares_Against_Its_Healthcare_Sector_Peers\"><\/span><strong>How Dr. Lal PathLabs Compares Against Its Healthcare Sector Peers<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets Dr. Lal PathLabs against 2 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P\/E, ROE and debt to equity, calculated across the 2 peer companies.<\/p>\n<table style=\"width:100%;border-collapse:collapse;\">\n<tr>\n<th style=\"border:1px solid #ddd;padding:8px;text-align:left;\">Company<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;text-align:left;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;text-align:left;\">P\/E<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;text-align:left;\">ROE<\/th>\n<th style=\"border:1px solid #ddd;padding:8px;text-align:left;\">Debt to Equity<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/lalpathlab\/dr-lal-pathlabs-ltd-share-price-today\">Dr. Lal PathLabs<\/a><\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">33,058<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">60.51<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">20.13%<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">0.08<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/metropolis\/metropolis-healthcare-ltd-share-price-today\">Metropolis Healthcare<\/a><\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">11,150<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">54.95<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">12.56%<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">0.15<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/vijaya\/vijaya-diagnostic-centre-ltd-share-price-today\">Vijaya Diagnostic Centre<\/a><\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">14,969<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">79.85<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">18.07%<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">0.44<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\"><strong>Peer average (2 companies)<\/strong><\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">&#8211;<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\"><strong>67.40<\/strong><\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\"><strong>15.32%<\/strong><\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\"><strong>0.29<\/strong><\/td>\n<\/tr>\n<\/table>\n<p>Against this peer set, Dr. Lal PathLabs&#8217;s 20.13% ROE is above the 15.32% peer average, and its P\/E of 60.51x runs below the peer average of 67.40x. Dr. Lal PathLabs&#8217; 60.51x P\/E is slightly below the 62.56x Industry P\/E and below the 67.40x peer average, backed by a 20.13% ROE that is higher than both Metropolis Healthcare and Vijaya Diagnostic Centre and a debt to equity ratio of 0.08, the lowest in the peer table.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Makes_Dr_Lal_PathLabs_Worth_Watching_in_Healthcare\"><\/span><strong>What Makes Dr. Lal PathLabs Worth Watching in Healthcare<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Returns:<\/strong> A 20.13% ROE is higher than Metropolis Healthcare at 12.56% and Vijaya Diagnostic Centre at 18.07%.<\/li>\n<li><strong>Valuation:<\/strong> A 60.51x P\/E is below Vijaya Diagnostic Centre at 79.85x but above Metropolis Healthcare at 54.95x.<\/li>\n<li><strong>Income:<\/strong> A dividend yield of 1.04% adds a modest income component.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Dr_Lal_PathLabs_Valuation_Is_It_Justified\"><\/span><strong>Dr. Lal PathLabs Valuation: Is It Justified?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Dr. Lal PathLabs&#8217; 60.51x P\/E is slightly below the 62.56x Industry P\/E and below the 67.40x peer average, backed by a 20.13% ROE that is higher than both Metropolis Healthcare and Vijaya Diagnostic Centre and a debt to equity ratio of 0.08, the lowest in the peer table. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.<\/p>\n<p style=\"font-style:italic;color:#000000;margin:14px 0;\">Also read &#8211; <a href=\"https:\/\/univest.in\/blogs\/sunpharma-best-stock-in-its-sector\">Is Sun Pharma the Best Stock in Its Sector? A Look at the Numbers<\/a><\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Dr. Lal PathLabs and other Healthcare sector stocks.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Track_Dr_Lal_PathLabs_Before_You_Invest\"><\/span><strong>How to Track Dr. Lal PathLabs Before You Invest<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Before deciding whether Dr. Lal PathLabs deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.<\/p>\n<ol>\n<li>Open the Univest Screener and search for Dr. Lal PathLabs to view live price, valuation ratios, and peer comparisons within the Healthcare sector.<\/li>\n<li>Compare its P\/E, P\/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.<\/li>\n<li>Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.<\/li>\n<li>Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.<\/li>\n<\/ol>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Dr. Lal PathLabs earns a place in the best stock in its sector conversation on the strength of a 20.13% ROE and a P\/E of 60.51x against a 62.56x Industry P\/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h3><span class=\"ez-toc-section\" id=\"Is_Dr_Lal_PathLabs_the_best_stock_in_its_sector\"><\/span><strong>Is Dr. Lal PathLabs the best stock in its sector?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Dr. Lal PathLabs has a 20.13% ROE and trades at 60.51x P\/E against a 62.56x Industry P\/E, and compares above the peer average ROE of 15.32% in this article&#8217;s named comparison, so the answer depends on what an investor is prioritising.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_current_share_price_of_Dr_Lal_PathLabs\"><\/span><strong>What is the current share price of Dr. Lal PathLabs?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Dr. Lal PathLabs was trading at Rs 1,949.50 on the NSE as of 13 October 2026, within its 52-week range of Rs 1,272.60 to Rs 2,038.60.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_sector_does_Dr_Lal_PathLabs_belong_to\"><\/span><strong>What sector does Dr. Lal PathLabs belong to?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Dr. Lal PathLabs is classified under the Healthcare sector on Univest.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_does_Dr_Lal_PathLabs_compare_to_its_sector_peers_on_PE\"><\/span><strong>How does Dr. Lal PathLabs compare to its sector peers on P\/E?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Dr. Lal PathLabs&#8217;s P\/E of 60.51x is below the 67.40x average of the 2 named peers compared in this article.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Dr_Lal_PathLabss_return_on_equity\"><\/span><strong>What is Dr. Lal PathLabs&#8217;s return on equity?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Dr. Lal PathLabs reported a return on equity of 20.13%, which is above the 15.32% average of its named peers in this comparison.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Should_I_invest_in_Dr_Lal_PathLabs_based_on_its_sector_position\"><\/span><strong>Should I invest in Dr. Lal PathLabs based on its sector position?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Dr. Lal PathLabs&#8217;s sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.<\/p>\n<p>{&#8220;@context&#8221;: &#8220;https:\/\/schema.org&#8221;, &#8220;@type&#8221;: &#8220;FAQPage&#8221;, &#8220;mainEntity&#8221;: [{&#8220;@type&#8221;: &#8220;Question&#8221;, &#8220;name&#8221;: &#8220;Is Dr. Lal PathLabs the best stock in its sector?&#8221;, &#8220;acceptedAnswer&#8221;: {&#8220;@type&#8221;: &#8220;Answer&#8221;, &#8220;text&#8221;: &#8220;Dr. Lal PathLabs has a 20.13% ROE and trades at 60.51x P\/E against a 62.56x Industry P\/E, and compares above the peer average ROE of 15.32% in this article&#8217;s named comparison, so the answer depends on what an investor is prioritising.&#8221;}}, {&#8220;@type&#8221;: &#8220;Question&#8221;, &#8220;name&#8221;: &#8220;What is the current share price of Dr. Lal PathLabs?&#8221;, &#8220;acceptedAnswer&#8221;: {&#8220;@type&#8221;: &#8220;Answer&#8221;, &#8220;text&#8221;: &#8220;Dr. Lal PathLabs was trading at Rs 1,949.50 on the NSE as of 13 October 2026, within its 52-week range of Rs 1,272.60 to Rs 2,038.60.&#8221;}}, {&#8220;@type&#8221;: &#8220;Question&#8221;, &#8220;name&#8221;: &#8220;What sector does Dr. Lal PathLabs belong to?&#8221;, &#8220;acceptedAnswer&#8221;: {&#8220;@type&#8221;: &#8220;Answer&#8221;, &#8220;text&#8221;: &#8220;Dr. Lal PathLabs is classified under the Healthcare sector on Univest.&#8221;}}, {&#8220;@type&#8221;: &#8220;Question&#8221;, &#8220;name&#8221;: &#8220;How does Dr. Lal PathLabs compare to its sector peers on P\/E?&#8221;, &#8220;acceptedAnswer&#8221;: {&#8220;@type&#8221;: &#8220;Answer&#8221;, &#8220;text&#8221;: &#8220;Dr. Lal PathLabs&#8217;s P\/E of 60.51x is below the 67.40x average of the 2 named peers compared in this article.&#8221;}}, {&#8220;@type&#8221;: &#8220;Question&#8221;, &#8220;name&#8221;: &#8220;What is Dr. Lal PathLabs&#8217;s return on equity?&#8221;, &#8220;acceptedAnswer&#8221;: {&#8220;@type&#8221;: &#8220;Answer&#8221;, &#8220;text&#8221;: &#8220;Dr. Lal PathLabs reported a return on equity of 20.13%, which is above the 15.32% average of its named peers in this comparison.&#8221;}}, {&#8220;@type&#8221;: &#8220;Question&#8221;, &#8220;name&#8221;: &#8220;Should I invest in Dr. Lal PathLabs based on its sector position?&#8221;, &#8220;acceptedAnswer&#8221;: {&#8220;@type&#8221;: &#8220;Answer&#8221;, &#8220;text&#8221;: &#8220;Dr. Lal PathLabs&#8217;s sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.&#8221;}}]}<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Is Dr. Lal PathLabs the best stock in its Healthcare sector? A data-driven comparison against named peers on P\/E, ROE and more.<\/p>\n","protected":false},"author":36,"featured_media":305446,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[5839,1019],"class_list":["post-305447","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-sector-stocks","tag-stock-market"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["305446"],"rank_math_title":["Is Dr. Lal PathLabs the Best Stock in Its Sector? A Look at the Numbers"],"rank_math_description":["Is Dr. Lal PathLabs the best stock in its Healthcare sector? A data-driven comparison against named peers on P\/E, ROE and more."],"rank_math_focus_keyword":["Is Dr. Lal PathLabs the Best Stock in Its Sector? A Look at the Numbers"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/is-dr-lal-pathlabs-the-best-stock-in-its-sector-a-look-at-the-numbers.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/305447","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/36"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=305447"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/305447\/revisions"}],"predecessor-version":[{"id":305448,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/305447\/revisions\/305448"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/305446"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=305447"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=305447"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=305447"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}